SBI Life Q4 FY26 preview: broker targets and key metrics

Why SBI Life is in focus before April 22

SBI Life Insurance Company Ltd (NSE: SBILIFE) is in the spotlight ahead of its Q4 FY26 earnings scheduled for April 22, 2026. The stock has also seen near-term momentum, with shares extending gains for a third straight session on Wednesday, March 18.

The build-up into results is being shaped by two factors investors track closely in life insurers: growth in annualised premium equivalent (APE) and profitability measured through value of new business (VNB) margin. Alongside these operating metrics, brokerage commentary has highlighted regulatory shifts and a premium valuation as key variables for near-term sentiment.

Motilal Oswal reiterates Buy, but trims target

Motilal Oswal Financial Services reiterated a ‘Buy’ rating on SBI Life and set a target price of ₹2,400 per share. The brokerage said the target implies a potential upside of 24% from the stock’s then current levels as of March 18, 2026.

At the same time, Motilal Oswal cut its target price from ₹2,570 to ₹2,400. The brokerage linked the revision to the possibility that new regulations could moderate growth in the short term, while maintaining that the company’s longer-term positioning remains favourable.

APE growth track record and the FY26-FY28 view

Motilal Oswal described SBI Life as a “consistent compounder” and backed that view with APE growth data. SBI Life’s APE grew at a 15% compound annual growth rate (CAGR) between FY20 and FY25, compared with industry APE growth of 6% over the same period.

The brokerage noted that momentum carried into FY26, with SBI Life reporting 15% year-on-year growth, compared with industry growth of 13%. It projected APE growth of around 15% annually through FY28.

Morgan Stanley, in a separate note, built in a more measured March-quarter expectation. It said it expects some moderation in APE growth in Q4 as SBI Life laps a strong base and pencilled in 10% APE growth for Q4. For FY26, Morgan Stanley forecast 14.5% APE growth, marginally above management’s guidance range of 13% to 14%.

Product mix shift: reducing ULIP dependence

Broker commentary has also focused on SBI Life’s product mix shift and its impact on profitability. Motilal Oswal highlighted that SBI Life has been consciously reducing its dependence on unit linked insurance plans (ULIPs), which now make up around 60% of its business.

The brokerage said the company has been pushing more profitable traditional and non-participating (non-par) products. The expectation is that a richer mix of protection and non-par products supports a stronger margin profile over time.

VNB margin guidance and how brokerages model it

SBI Life management has reaffirmed guidance for VNB margins to remain in the 26% to 28% range for FY26. Motilal Oswal attributed the confidence to an improving product mix, higher contribution from protection products, and operational efficiencies. It projected that VNB margin could reach 28.5% by FY28.

Morgan Stanley said SBI Life’s Q3 margin beat was driven by stronger protection margins and improved product profitability, helped by operating leverage and higher rider attachment. It also flagged a GST-related negative impact that management estimated at around 150 basis points, and said SBI Life expects the GST drag to ease to about 30 to 40 basis points by Q4.

For FY26, Morgan Stanley pencilled in a 28% VNB margin, at the upper end of management guidance, and expects 1 percentage point margin expansion in each of FY27 and FY28. It forecast VNB to grow at a 17% CAGR over FY26 to FY28.

Valuation: premium multiple remains a sensitivity

Motilal Oswal noted that SBI Life trades at a premium valuation versus some peers. It cited a price-to-earnings (P/E) ratio of approximately 78.16, higher than ICICI Prudential Life but comparable to HDFC Life.

The brokerage said a high valuation can become a risk if growth slows or regulatory headwinds intensify. This is also why commentary ahead of results is leaning heavily on whether growth and margins remain within guided ranges.

Other brokerage targets: ₹2,200 to ₹2,550 in view

Motilal Oswal’s ₹2,400 target sits above some other estimates mentioned alongside the stock. Price targets from brokerages such as Nuvama and JM Financial were cited in the ₹2,200 to ₹2,320 range.

Morgan Stanley, meanwhile, raised its price target to ₹2,550 from ₹2,510 and maintained an Overweight rating. It said the revised target implies around 24% upside, valuing the stock at 17x FY28 embedded value and VNB.

FY25 as a reference point: key reported metrics

While the market is focused on Q4 FY26, some FY25 operating and financial disclosures provide context on what investors tend to track.

For Q4 FY25, SBI Life reported consolidated net profit of ₹813.5 crore, compared with ₹810.8 crore in Q4 FY24. Net premium income declined 5% year-on-year to ₹23,861 crore from ₹25,116 crore. First-year premium increased 7.3% year-on-year to ₹4,858.7 crore, and renewal premium rose 12.9% to ₹14,680.3 crore.

SBI Life reported assets under management (AUM) of ₹4,48,000 crore as of March 31, 2025, up 15% year-on-year, with a debt-equity mix of 61:39. It also disclosed that 94% of its debt investments were in AAA-rated or sovereign instruments. Persistency improved, with the 13th-month ratio at 86.64% and the 61st-month ratio at 61.51%.

Key numbers snapshot

What investors will track in Q4 FY26 commentary

Broker notes suggest the market will focus on whether SBI Life stays within its stated growth and margin bands, especially given the discussion around regulatory changes and distribution economics. Management’s view on the product mix shift away from ULIPs, and the pace at which protection and non-par products scale, is also likely to remain central.

The other theme is whether the margin headwinds discussed earlier, including the GST-related drag described by management and referenced by Morgan Stanley, continue to ease as expected into Q4. And given the premium valuation cited by Motilal Oswal, even small deviations from guided ranges can influence near-term stock reactions.

Conclusion

Ahead of SBI Life’s April 22, 2026 results, brokerages have stayed largely constructive while highlighting a tighter risk-reward due to regulation and valuation. Motilal Oswal’s ₹2,400 target and Morgan Stanley’s ₹2,550 target frame expectations, with APE growth and VNB margin delivery likely to be the key swing factors after the earnings release.